All fair points trding. I don't believe that NP has accomplished nothing (to the contrary, as you correctly note) and am not advocating that NP be replaced. Hitting PE in a PIII trial is a major accomplishment. Taking leronlimab off Progenics' shelf to where it is today is also a major accomplishment.
However, I do believe there has been some "learning on the job" from CYDY's entire management team, not just NP, and that shareholders have suffered because of that fact. Examples of this, IMO, include the recent stability delay, the failure to do a dose escalation portion initially in combo trial (resulting in the recent dosing uncertainty), and the recent, very strange, TNBC issues.
Although I don't have perfect information, I also find it hard to believe that CYDY, with a drug like leronlimab, has remained on the OTC for another year and a half after hitting PE in a Phase III trial, continuing to raise cash with the broken shares + warrants model that we all know (and have known for the last 2 years) was resulting in the SP being where it is today.
On the topic of OTC, we also have never received an explanation for the total debacle that was the declaration of intention to RS/uplist last year, followed by calling that off after the SP got slammed. Note that I am NOT trying to debate the wisdom of RS vs. Organic as a means to uplist. I am simply stating that the whole episode was handled very poorly, and it cost shareholders dearly.
More than anything, though, my frustrations stem from the near-constant overpromise and underdeliver that CYDY has fed shareholders in all contexts since I invested (March 2017).
I used to work in the restaurant industry, and the rule for what to tell the customer who is waiting for a table was simple. Take the amount of time that you think it will be (say, 30 minutes), and increase it by 50%-100% (call it an hour). That way, when they get their table in less than the hour wait you told them, they are happy and think you did right by them.
I think we, as shareholders, would be much happier right now if the company line had always been "BLA by end of 2019". Underpromise. Overdeliver.
Sorry for the long-winded post. Wanted to clarify that I am not totally opposed to NP or CYDY management. He and they have done good things.
However, it is time to deliver for shareholders or the BOD should fulfill its fiduciary duties and find those who can!
Good luck to us all. I am starting to think we need it.
However, I do believe there has been some "learning on the job" from CYDY's entire management team, not just NP, and that shareholders have suffered because of that fact. Examples of this, IMO, include the recent stability delay, the failure to do a dose escalation portion initially in combo trial (resulting in the recent dosing uncertainty), and the recent, very strange, TNBC issues.
Although I don't have perfect information, I also find it hard to believe that CYDY, with a drug like leronlimab, has remained on the OTC for another year and a half after hitting PE in a Phase III trial, continuing to raise cash with the broken shares + warrants model that we all know (and have known for the last 2 years) was resulting in the SP being where it is today.
On the topic of OTC, we also have never received an explanation for the total debacle that was the declaration of intention to RS/uplist last year, followed by calling that off after the SP got slammed. Note that I am NOT trying to debate the wisdom of RS vs. Organic as a means to uplist. I am simply stating that the whole episode was handled very poorly, and it cost shareholders dearly.
More than anything, though, my frustrations stem from the near-constant overpromise and underdeliver that CYDY has fed shareholders in all contexts since I invested (March 2017).
I used to work in the restaurant industry, and the rule for what to tell the customer who is waiting for a table was simple. Take the amount of time that you think it will be (say, 30 minutes), and increase it by 50%-100% (call it an hour). That way, when they get their table in less than the hour wait you told them, they are happy and think you did right by them.
I think we, as shareholders, would be much happier right now if the company line had always been "BLA by end of 2019". Underpromise. Overdeliver.
Sorry for the long-winded post. Wanted to clarify that I am not totally opposed to NP or CYDY management. He and they have done good things.
However, it is time to deliver for shareholders or the BOD should fulfill its fiduciary duties and find those who can!
Good luck to us all. I am starting to think we need it.
